Oncotelic's Sapu Nano to Showcase Nanomedicine Platform at BIO-Europe 2026

Oncotelic Therapeutics (OTCQB: OTLC) has announced that its subsidiary, Sapu Nano, will showcase its innovative Deciparticle (TM) nanomedicine platform and clinical pipeline at the prestigious BIO-Europe Spring 2026 conference on March 25, where it has been selected as a presenting company. The presentation will highlight this next-generation drug delivery technology designed to improve therapeutic efficacy and unlock new clinical potential, particularly in oncology. The company will feature two lead candidates: Sapu003 (Everolimus for Injection), currently in Phase 1 clinical trials, and Sapu006 (Docetaxel for Injection), which is entering Phase 1 studies. This appearance at BIO-Europe Spring 2026 is a strategic move as Oncotelic and Sapu Nano actively seek partnerships to advance the development and commercialization of these promising nanomedicine therapies.

Oncotelic Therapeutics, formerly known as Mateon Therapeutics and OXiGENE, has a deep history in oncology drug development dating back to 1988, with a special emphasis on improving outcomes for rare pediatric cancers. The company holds rare pediatric designations for conditions like Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503. Beyond oncology, Oncotelic has expanded its portfolio through acquisitions, including PointR Data Inc. to build an AI-driven biotechnology company and AL-101 for intranasal apomorphine delivery targeting Parkinson's Disease and sexual disorders. For more details, investors can refer to the company's newsroom at https://ibn.fm/OTLC or view the full press release at https://ibn.fm/Slq47.

This news was distributed via BioMedWire (BMW), a specialized communications platform within the Dynamic Brand Portfolio of IBN, focusing on biotechnology and life sciences. BioMedWire provides comprehensive services including wire solutions, editorial syndication to over 5,000 outlets, press release enhancement, and social media distribution to ensure maximum reach and impact for its clients. By leveraging such platforms, Oncotelic aims to gain significant recognition among investors, journalists, and the general public, cutting through market noise to highlight its advancements in nanomedicine and strategic initiatives at key industry events like BIO-Europe Spring 2026.